<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Biofilms Microbiomes</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Biofilms Microbiomes</journal-id><journal-id journal-id-type="pmc-domain-id">3133</journal-id><journal-id journal-id-type="pmc-domain">npjbiofilms</journal-id><journal-title-group><journal-title>NPJ Biofilms and Microbiomes</journal-title></journal-title-group><issn pub-type="epub">2055-5008</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475161</article-id><article-id pub-id-type="pmcid-ver">PMC12475161.1</article-id><article-id pub-id-type="pmcaid">12475161</article-id><article-id pub-id-type="pmcaiid">12475161</article-id><article-id pub-id-type="pmid">41006325</article-id><article-id pub-id-type="doi">10.1038/s41522-025-00827-2</article-id><article-id pub-id-type="publisher-id">827</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Intestinal fungal signatures and their impact on immune checkpoint inhibitor efficacy: a multi-cohort meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="DD">Ding-Ding</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="J">Jia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="ZJ">Zhi-Jun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shu</surname><given-names initials="XL">Xian-Long</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="RM">Rui-Meng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="YC">Yong-Chao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="HH">Hong-Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zou</surname><given-names initials="Y">You</given-names></name><address><email>zouyou@csu.edu.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="R">Rong</given-names></name><address><email>liuronghyw@csu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Clinical Pharmacology, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, PR China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Institute of Clinical Pharmacology, Central South University, </institution><institution>Hunan Key Laboratory of Pharmacogenetics, </institution></institution-wrap>Changsha, PR China </aff><aff id="Aff3"><label>3</label>Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, PR China </aff><aff id="Aff4"><label>4</label>National Clinical Research Center for Geriatric Disorders, Changsha, Hunan PR China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Information and Network center, </institution><institution>Central South University, </institution></institution-wrap>Changsha, PR China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">478289</issue-id><elocation-id>188</elocation-id><history><date date-type="received"><day>1</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 17:25:21.950"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41522_2025_Article_827.pdf"/><abstract id="Abs1"><p id="Par1">Gut microbiota influence on the effectiveness of immune checkpoint inhibitors (ICIs), but research on fungi&#8212;an essential component of the microbiome&#8212;has been limited. This multi-cohort meta-analysis of 976 fecal metagenomes across 8 cohorts, representing melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), identified fungal species associated with ICI efficacy. In melanoma, <italic toggle="yes">Rhizophagus irregularis</italic> and <italic toggle="yes">Debaryomyces hansenii</italic> were correlated with poor responses, whereas <italic toggle="yes">Aspergillus avenaceus</italic> was associated with great efficacy. In NSCLC, an increased abundance of <italic toggle="yes">Aspergillus pseudonomiae</italic> was associated with a favorable prognosis. Stronger bacterial-fungal interactions were observed in responders. The presence of certain fungi in fungal enterotypes, like <italic toggle="yes">Aspergillus</italic> or <italic toggle="yes">Saccharomyces</italic>, was linked to better efficacy to ICIs. Mouse models revealed <italic toggle="yes">Debaryomyces hansenii</italic> impaired ICI efficacy by reducing CD8+ T cells. Our findings highlight specific fungal signatures that may inform strategies to enhance ICI efficacy and encourage further research on microbial impacts on treatment outcomes.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Metagenomics</kwd><kwd>Microbiota</kwd><kwd>Clinical microbiology</kwd></kwd-group><funding-group><award-group><funding-source><institution>the National Key Research and Development Program</institution></funding-source><award-id>2021YFA1301200</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the National Scientific Foundation of China</institution></funding-source><award-id>No. 82474022, 31801121, 82373961</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Hunan Provincial Science and Technology Innovation Plan Project</institution></funding-source><award-id>2022RC1022</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have significantly improved clinical outcomes for cancer patients<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Nonetheless, variability in individual responses and tumor heterogeneity affects the overall effectiveness of these therapies<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. In addition to patient-specific physiological characteristics, emerging research suggests that gut microbiota influences the effectiveness of ICIs<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Most studies to date have focused on gut bacteria, with some identified as potential biomarkers for immunotherapy or therapeutic adjuvants<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. However, the gut also hosts fungi, archaea, and viruses, which are increasingly recognized for their roles in disease progression and immune regulation<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Consequently, the impact of intestinal fungi on ICI efficacy warrants further investigation. Furthermore, the balance of the intestinal immune system relies on the interactions between gut fungi and bacteria. Yet, the association between these microbial communities and ICI response phenotypes remains unclear. Understanding how gut bacteria and fungi interact may provide valuable insights into enhancing ICI effectiveness and addressing the variability observed in patient responses.</p><p id="Par3">The current landscape of intestinal fungal bioinformatics is limited due to the lack of a comprehensive database for fungal taxonomic sequences<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. However, researchers have managed to address this gap by integrating multiple fungal reference genome databases, demonstrating a resourceful approach to the problem<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref></sup>. Moreover, there is considerable variability in the microbial signatures reported in existing studies. This inconsistency arises from a range of factors, including host physiology, dietary habits, geographic location, and environmental conditions, as well as technical aspects such as sample quality, sequencing depth, and the analysis pipeline used for biological data<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. To increase the consistency and reliability of findings related to the efficacy of ICIs, employing meta-analysis alongside multi-cohort sequencing data represents an effective research strategy. This approach can help identify microbial signatures associated with ICI effectiveness and improve our understanding of their role in treatment outcomes.</p><p id="Par4">Here, we collected and analyzed fecal shotgun metagenomic data from 8 cohorts prior to treatment with ICIs. After performing quality control and filtering, a total of 976 samples were retained in the subsequent analysis. Logistic regression and Cox regression models were used to identify microbiological species associated with ICI efficacy in different cohorts and cancer types, and meta-analysis was then conducted to pinpoint microbial signatures relevant to cross-cohort comparisons. Recognizing that microorganisms may function as communities, we identified three fungal enterotypes, with the <italic toggle="yes">Aspergillus-</italic>dominated enterotype in melanoma and the <italic toggle="yes">Saccharomyces</italic>-dominated enterotype in non-small cell lung cancer (NSCLC) associated with improved ICI efficacy. Furthermore, our experiments in mice confirmed that <italic toggle="yes">Debaryomyces hansenii</italic> can diminish the effectiveness of PD-1 monoclonal antibody (mAb) in melanoma. Overall, our findings highlight and validate the role of specific intestinal fungal species in influencing ICI effectiveness. This underscores the importance of considering intestinal fungi in cancer treatment strategies involving ICIs and provides valuable insights for future research in this area.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Clinical features and microbiological characteristics</title><p id="Par5">The study framework is illustrated in Fig. <xref rid="Fig1" ref-type="fig">1a</xref>. After excluding samples that were not treated with ICI and those that were not sequenced at baseline, 1161 samples from eight cohorts were included for further analysis. To minimize technological bias in our bioinformatics analysis, we applied a standard species annotation protocol to all metagenomic sequencing data. The median metagenomic reads count and ratio mapped to fungi were 631 (10<sup>2.8</sup>) and 0.025% (10<sup>&#8722;3.61</sup>, Fig. <xref rid="Fig1" ref-type="fig">1b</xref>), respectively, which is lower than the 0.1% reported in previous publications<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. We found that there was a positive correlation between the sequencing depth of the samples and the fraction of fungi-read (<italic toggle="yes">r</italic>&#8201;=&#8201;0.73, Supplementary Fig. <xref rid="MOESM1" ref-type="media">1a</xref>) through the Person correlation analysis. Additionally, the sequencing ratio varied across different tumor types, likely due to differences in sequencing techniques and cohort characteristics (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1b, c</xref>). A total of 504 fungi and 3216 bacteria were detected across all eight cohorts (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2a, b</xref>). The median of species mapped to fungi and bacteria per sample was 124 and 1415, respectively (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2c, d</xref>). To ensure the reliability of our edibility follow-up study, we further filtered the samples, with details outlined in Fig. <xref rid="Fig1" ref-type="fig">1c</xref> and Supplementary Data <xref rid="MOESM3" ref-type="media">1</xref>. This process resulted in a final dataset of 976 samples, including 301 responders (30.8%) and 650 non-responders (66.6%). The results of Chi-square (&#967;<sup>2</sup>) test showed that sample filtration did not alter the distribution of ICI response proportions from the original dataset (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). Additional details regarding other clinical indicators are provided in Supplementary Data <xref rid="MOESM3" ref-type="media">2</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Sample pre-processing and fungal profiles in responders and non-responders.</title><p><bold>a</bold> Flow chart for this study; <bold>b</bold> Top panel: the count number of bacterial (left) or fungal (right) reads in 8 cohorts (<italic toggle="yes">n</italic>&#8201;=&#8201;1161). Bottom panel: the ratio of fungal to bacterial read count number in all samples; <bold>c</bold> Sample quality control procedures and criteria; <bold>d</bold> The change in the proportion of responder before and after filtration in each tumor; &#967;<sup>2</sup> test was used for evaluation; <bold>e</bold> Fungal composition at the phylum level for responders and non-responders in each tumor; the relative abundance of each phylum is averaged.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e414" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig1_HTML.jpg"/></fig></p><p id="Par6">The relative abundance of the two major fungal phyla, <italic toggle="yes">Ascomycota</italic> and <italic toggle="yes">Basidiomycota</italic>, in responders versus non-responders was presented in Fig. <xref rid="Fig1" ref-type="fig">1e</xref>. Notably, the fungal Shannon index did not show statistically significant differences between responders and non-responders across various cohorts (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3a</xref>). However, across all cohorts, the fungal Shannon index was statistically different among response groups only in melanoma (<italic toggle="yes">P</italic>&#8201;=&#8201;0.0018) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3b</xref>). The Shannon index of fungi was influenced by covariates such as cohort, age, gender, and body mass index (BMI) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3c&#8211;e</xref>). Additionally, we observed differences in &#946;-diversity between responders and non-responders in melanoma (<italic toggle="yes">PERMANOVA P</italic>&#8201;=&#8201;0.002), NSCLC (<italic toggle="yes">PERMANOVA P</italic>&#8201;=&#8201;0.44), and renal cell carcinoma (RCC) (<italic toggle="yes">PERMANOVA P</italic>&#8201;=&#8201;0.63) after adjusting for the influence of covariates (cohort, age, gender, and BMI). Consistent with the &#945;-diversity analysis, the results of the principal coordinate analysis indicated that the heterogeneity of the cohort had a greater impact on fungal diversity than other variables (age, gender, and BMI) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>).</p></sec><sec id="Sec4"><title>Microbial signatures associated with ICI efficacy were identified</title><p id="Par7">To identify microbial signatures associated with ICI efficacy, logistic regression was performed. Using the criteria of a meta <italic toggle="yes">p</italic>-value threshold of less than 0.05 and a heterogeneity <italic toggle="yes">p</italic>-value greater than 0.05, we identified 27 fungi (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>) and 23 bacteria (Supplementary Data <xref rid="MOESM3" ref-type="media">4</xref>), of which 13 fungi and 11 bacteria were positively associated with response to ICIs in melanoma. Additionally, there were 34 bacteria (Supplementary Data <xref rid="MOESM3" ref-type="media">5</xref>) and 25 fungi (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>) that were significantly associated with PFS12 (PFS at 12 months). Notably, high levels of abundance of <italic toggle="yes">Rhizophagus irregularis</italic> (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>) were linked to decreased ICI efficacy (Meta OR&#8201;=&#8201;0.67, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.0036) and PFS12 (Meta OR&#8201;=&#8201;0.71, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.028), while <italic toggle="yes">Aspergillus avenaceus</italic> (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>) was associated with improved ICI efficacy (Meta OR&#8201;=&#8201;1.66, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.002) and PFS12 (Meta OR&#8201;=&#8201;1.66, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.004). In multivariate Cox regression analysis, 15 fungi (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>) and 26 bacteria (Supplementary Data <xref rid="MOESM3" ref-type="media">7</xref>) were identified as influencing progression-free survival (PFS), organized by calculated risk scores. A high abundance of <italic toggle="yes">Hericium alpestre</italic> was linked to longer PFS (Meta HR&#8201;=&#8201;0.50, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.003, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.071 in the merged cohorts, Fig. <xref rid="Fig2" ref-type="fig">2e</xref>), while <italic toggle="yes">Tilletiopsis washingtonensis</italic> showed the opposite effect (Meta HR&#8201;=&#8201;1.71, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.009, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.0011 in the merged cohorts, Fig. <xref rid="Fig2" ref-type="fig">2f</xref>). Due to the limited sample size, results for other indicators, such as PFS6 (PFS at 6 months) and overall survival (OS), are presented in Supplementary Data <xref rid="MOESM3" ref-type="media">6</xref> and <xref rid="MOESM3" ref-type="media">8</xref>. When accounting for covariates such as gender, age, and BMI, univariate logistic regression and univariate Cox regression analysis revealed that only BMI significantly affected clinical indicators (Supplementary Data <xref rid="MOESM3" ref-type="media">3</xref>). Additionally, confounder analysis indicated that the cohort had a greater influence on fungal abundance (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5a</xref>). The bacterial signatures associated with ICI efficacy in melanoma are detailed in Supplementary Data <xref rid="MOESM3" ref-type="media">6</xref>&#8211;<xref rid="MOESM3" ref-type="media">8</xref>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Fungal signatures associated with response to ICIs in melanoma.</title><p><bold>a</bold> Heatmaps of &#946; value for response and PFS12; *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; gray: NA; <bold>b</bold> Details of the association between <italic toggle="yes">Rhizophagus irregularis</italic> and response (left)/ PFS12 (right) in each cohort; <bold>c</bold> Details of the association between <italic toggle="yes">Aspergillus avenaceus</italic> and response (left)/ PFS12 (right) in each cohort; <bold>d</bold> Risk scores model for PFS; <bold>e</bold> Survival curve plots for <italic toggle="yes">Hericium alpestre</italic> versus PFS; <italic toggle="yes">P</italic>-values are determined by the log-rank tests. <bold>f</bold> Survival curve plots for <italic toggle="yes">Tilletiopsis washingtonensis</italic> versus PFS; <italic toggle="yes">P</italic>-values are determined by the log-rank tests.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e601" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig2_HTML.jpg"/></fig></p><p id="Par8">In NSCLC, 23 fungi and 38 bacteria (Supplementary Data <xref rid="MOESM3" ref-type="media">9</xref>) were linked to the effectiveness of ICIs, while 17 fungi and 47 bacteria (Supplementary Data <xref rid="MOESM3" ref-type="media">10</xref>) were associated with PFS6 (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). However, detailed information regarding PFS12 (Supplementary Data <xref rid="MOESM3" ref-type="media">11</xref>), PFS (Supplementary Data <xref rid="MOESM3" ref-type="media">12</xref>), and OS (Supplementary Data <xref rid="MOESM3" ref-type="media">13</xref>) was only available from the cohort of DerosaL_2024, preventing a comprehensive meta-analysis, and a <italic toggle="yes">p</italic>-value of less than 0.05 was considered as an associated species. The fungal markers associated with OS were identified by Cox regression analysis adjusting covariates (age, gender, BMI, and read-depth), and the results of the high and low groups divided according to the median risk score were depicted in Fig. <xref rid="Fig3" ref-type="fig">3b</xref>. Notably, high abundance of <italic toggle="yes">Aspergillus pseudonomiae</italic> was associated with the improved effectiveness of ICIs (Meta OR&#8201;=&#8201;1.28, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.077, Fig. <xref rid="Fig3" ref-type="fig">3c</xref>), increased percentage of patients with PFS6 (Meta OR&#8201;=&#8201;1.44, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.004), and longer PFS (HR&#8201;=&#8201;0.75, <italic toggle="yes">P</italic>&#8201;=&#8201;0.0004, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.00014) and OS (HR&#8201;=&#8201;0.71, <italic toggle="yes">P</italic>&#8201;=&#8201;0.0009, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.00041, Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). High abundance of <italic toggle="yes">Saccharomyces cerevisiae</italic> (Meta OR&#8201;=&#8201;0.74, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.036) was linked to impaired effectiveness of ICIs, while <italic toggle="yes">Fusarium flagelliforme</italic> (Meta OR&#8201;=&#8201;1.39, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.005) was associated with an increased percentage of individuals with PFS6 (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). Patients with high abundance of <italic toggle="yes">Schizosaccharomyces japonicus</italic> (HR&#8201;=&#8201;0.85, <italic toggle="yes">P</italic>&#8201;=&#8201;0.032, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.029) experienced longer PFS, whereas those with high abundance of <italic toggle="yes">Malassezia globosa</italic> (HR&#8201;=&#8201;1.21, <italic toggle="yes">P</italic>&#8201;=&#8201;0.032, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.0061) had shorter OS (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). The results of confounding variable analysis are presented in Supplementary Fig. <xref rid="MOESM1" ref-type="media">5b</xref>, and the bacterial signatures related to ICI treatment in NSCLC were shown in Supplementary Data <xref rid="MOESM3" ref-type="media">9</xref>&#8211;<xref rid="MOESM3" ref-type="media">13</xref>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Fungal signatures associated with response to ICIs in NSCLC.</title><p><bold>a</bold> Heatmaps of &#946; value for response and PFS6; *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; gray: NA; <bold>b</bold> Risk scores model for OS; <bold>c</bold> Details of the association between <italic toggle="yes">Aspergillus pseudonomiae</italic> and response (left)/ PFS6 (right) in each cohort; <bold>d</bold> Survival curve plots for <italic toggle="yes">Aspergillus pseudonomiae</italic> versus PFS (left) and OS (right); <italic toggle="yes">P</italic>-values are determined by the log-rank tests; <bold>e</bold> Details of the association between <italic toggle="yes">Saccharomyces cerevisiae</italic> and response (left) in each cohort; Details of the association between <italic toggle="yes">Fusarium flagelliforme</italic> and PFS6 (right) in each cohort; <bold>f</bold> Survival curve plots for <italic toggle="yes">Schizosaccharomyces japonicus</italic> versus PFS (left); Survival curve plots for <italic toggle="yes">Malassezia globosa</italic> versus OS (right); <italic toggle="yes">P</italic>-values are determined by the log-rank tests.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e762" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig3_HTML.jpg"/></fig></p><p id="Par9">In RCC, the association analysis results may be biased due to the small sample size and low percentage of responders. The associations between microbial abundance, PFS6, and response are detailed in Supplementary Data <xref rid="MOESM3" ref-type="media">14</xref>.</p></sec><sec id="Sec5"><title>The correlation of microbial pairs varied among groups of response</title><p id="Par10">The presence of microbial interactions is a common phenomenon, so we explore the role of correlations between the bacterial and fungal kingdoms during ICI therapy. Overall, we found that in melanoma, the ecological network was more complex in responders (90 species, 2995 associations) compared to non-responders (90 species, 2149 associations) (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). In contrast, the trend is reversed in NSCLC, where responders exhibited 102 species and 807 associations, while non-responders had 92 species and 1170 associations (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). In addition to the robust connections among species within the kingdom, there are also substantial interactions between fungi and bacteria. Notably, responders demonstrated a higher degree of positive connection, regardless of whether they had NSCLC or melanoma (Fig. <xref rid="Fig4" ref-type="fig">4a, b</xref>). Consistently, a similar interaction pattern appears once the weak connection was eliminated in melanoma (|r|&lt;0.55, Fig. <xref rid="Fig4" ref-type="fig">4c</xref>). After removing the weakly correlated microbial pairs, a trend was observed in NSCLC where the correlation was slightly stronger in responders than in non-responders (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). Furthermore, in melanoma responders, a higher proportion of fungal interkingdom interactions (<italic toggle="yes">Vanrija humicola</italic>, <italic toggle="yes">Tilletiopsis washingtonensis</italic>, <italic toggle="yes">Phanerodontia chrysosporium</italic>, <italic toggle="yes">Pyrenophora seminiperda</italic>) could be observed, while in NSCLC, the interactions among the <italic toggle="yes">Faecalibacterium</italic> (<italic toggle="yes">Faecalibacterium prausnitzii</italic>, <italic toggle="yes">Faecalibacterium duncaniae</italic>, <italic toggle="yes">Faecalibaculum rodentium</italic>) were also more pronounced.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Coabundance correlations among multi-kingdom species in responders and non-responders.</title><p><bold>a</bold> Summary of type of correlation and microbial pairs involving combined species related to ICI efficacy (Meta <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1) from bacteria and fungi in melanoma; Only significant (FDR&#8201;&lt;&#8201;0.05) absolute correlations above 0.2 are shown; <bold>b</bold> Summary of type of correlation and microbial pairs involving combined species related to ICI efficacy (Meta <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1) from bacteria and fungi in NSCLC; Only significant (FDR&#8201;&lt;&#8201;0.05) absolute correlations above 0.2 are shown; <bold>c</bold> Coabundance networks involving combined species related to ICI efficacy (Meta <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1) from bacteria and fungi in melanoma; Only significant (FDR&#8201;&lt;&#8201;0.05) absolute correlations above 0.55 are shown; <bold>d</bold> Coabundance networks involving combined species related to ICI efficacy (Meta <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1) from bacteria and fungi in NSCLC; Only significant (FDR&#8201;&lt;&#8201;0.05) absolute correlations above 0.55 are shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e845" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig4_HTML.jpg"/></fig></p><p id="Par11">We identified significant differences in microbial pairs among responders and non-responders, with 524 pairs in melanoma and 33 pairs in NSCLC (Supplementary Data <xref rid="MOESM3" ref-type="media">15</xref>&#8211;<xref rid="MOESM3" ref-type="media">17</xref>), which may contribute to the effectiveness of ICI therapy. In melanoma, this change in correlations between groups was mostly observed between fungi and fungi, as well as between fungi and bacteria (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6a</xref>). However, in NSCLC, it was mostly found within the bacterial interkingdom. The cause of this difference cannot be ruled out as being due to the lower proportion of responders or the lower sequencing depth in NSCLC. Among these different microbial pairs, the correlation of responders was stronger than that of non-responders, whether in melanoma or in NSCLC (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6b</xref>). Furthermore, we calculated correlations between the abundances of species that met the criteria for ICI prognostic association analysis in the different groups (responders vs. non-responders), then considered the species in differential microbial pairs (empirical <italic toggle="yes">P</italic>&#8201;&lt;&#8201;10<sup>&#8722;5</sup>) as key nodes. We then overlapped these nodes and microbial signatures associated with ICI response. On the whole, we found the presence of low overlap (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6c, d</xref>), which suggests that the abundance changes of the microbiome and the interaction network may be relatively independent. However, a few overlapping species (such as <italic toggle="yes">Colletotrichum asianum</italic> and <italic toggle="yes">Klebsiella oxytoca</italic>) may have a dual effect of &#8220;abundance and interaction&#8221;, which is worthy of verification by subsequent experiments.</p></sec><sec id="Sec6"><title>Fungal enterotypes are associated with the response to ICI therapy</title><p id="Par12">Microbes may function as classes or groups, whereas the enterotype is a stable microbial community that remains unaffected by covariates<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. In this study, we identified three distinct fungal enterotypes using the Bray&#8211;Curtis distance by PAM (<italic toggle="yes">PERMANOVA P</italic>&#8201;=&#8201;0.001, Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Based on the genera with the highest average relative abundance as the characteristics of enterotype, they were divided into <italic toggle="yes">Asper_high</italic>, <italic toggle="yes">Sacc_type</italic>, and <italic toggle="yes">Asper_low</italic> (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). <italic toggle="yes">Aspergillus</italic> and <italic toggle="yes">Saccharomyces</italic>, as the dominant genera in all enterotypes, exhibited significant differences in relative abundance across the different enterotypes (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>). Meanwhile, there were significant differences in species diversity among the three fungal enterotypes, with the <italic toggle="yes">Asper_low</italic> having a higher Shannon index (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Association between fungal enterotypes and ICI efficacy.</title><p><bold>a</bold> PCoA diagram of fungal enterotypes based on Bray-Curtis distance by PAM; <bold>b</bold> Genera in the top 10 in mean relative abundance among the three fungal enterotypes; <bold>c</bold> Comparison of abundance difference of dominant genera in the three fungal enterotypes by Wilcoxon test; left: <italic toggle="yes">Aspergillus;</italic> right: <italic toggle="yes">Saccharomyces</italic>; <bold>d</bold> Comparison of Shannon index difference in the three fungal enterotypes by Wilcoxon test; <bold>e</bold> Association between fungal enterotypes and ICI efficacy in melanoma (left) and NSCLC (right); &#967;<sup>2</sup> test was used for evaluation; <bold>f</bold>, <bold>g</bold> Survival curve plots for fungal enterotypes versus PFS (left) and OS (right) in melanoma; <italic toggle="yes">P</italic>-values are determined by the log-rank tests; *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e968" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig5_HTML.jpg"/></fig></p><p id="Par13">There were differences in the proportions of responders among the three fungal enterotypes (Fig. <xref rid="Fig5" ref-type="fig">5e</xref>). Among them, the <italic toggle="yes">Asper_high</italic> had a higher proportion of responders in melanoma (<italic toggle="yes">P</italic>&#8201;=&#8201;0.0027), while in NSCLC, the proportion of the <italic toggle="yes">Sacc_type</italic> was higher (<italic toggle="yes">P</italic>&#8201;=&#8201;0.043). The fungal enterotypes had no significant association with PFS6 (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7a</xref>), but the <italic toggle="yes">Sacc_type</italic> showed a higher proportion of PFS12 individuals (<italic toggle="yes">P</italic>&#8201;=&#8201;0.0062, Supplementary Fig. <xref rid="MOESM1" ref-type="media">7b</xref>) in melanoma. Due to the limitation of sample size, no similar trend was observed in RCC (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7c</xref>). Meanwhile, patients with the the <italic toggle="yes">Asper_low</italic> have shorter PFS (log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.019, Fig. <xref rid="Fig6" ref-type="fig">6f</xref>) and OS (log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;0.016, Fig. <xref rid="Fig6" ref-type="fig">6g</xref>) in melanoma, while there was no significant difference in PFS and OS among these three fungal enterotypes in NSCLC (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7d, e</xref>). Additionally, we analyzed bacterial enterotypes, classifying them into two groups based on the abundance of <italic toggle="yes">Bacteroides</italic>: <italic toggle="yes">Bac_high</italic> and <italic toggle="yes">Bac_low</italic> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">8a&#8211;c</xref>). However, these bacterial enterotypes were not statistically associated with the efficacy of ICIs (Supplementary Fig. <xref rid="MOESM1" ref-type="media">8d</xref>). We also did not find an association between bacterial enterotypes and fungal enterotypes (Supplementary Fig. <xref rid="MOESM1" ref-type="media">8e</xref>). Interestingly, we noted varying distributions of fungal enterotypes across different cancers and cohorts, with the <italic toggle="yes">Sacc_type</italic> predominant in NSCLC and the <italic toggle="yes">Asper_low</italic> more common in melanoma (Supplementary Fig. <xref rid="MOESM1" ref-type="media">8f</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>Functional validation of <italic toggle="yes">Debaryomyces hansenii</italic> in mice.</title><p><bold>a</bold> Details of the association between <italic toggle="yes">Debaryomyces hansenii</italic> and response in each cohort of melanoma; <bold>b</bold> The experimental design of mice included the dose of <italic toggle="yes">Debaryomyces hansenii</italic> and the treatment plan of PD-1 mAb; <bold>c</bold> The relative abundance of <italic toggle="yes">Debaryomyces hansenii</italic> in the stool of the gavage and the non-gavage at the end of the experiment by ITS sequencing<italic toggle="yes">;</italic>
<italic toggle="yes">P</italic>-values are determined by Wilcoxon test; <bold>d</bold> Tumor growth curves measured every two days; Tumor volume (mm<sup>3</sup>) was calculated as: (shortest diameter)<sup>2</sup>&#8201;&#215;&#8201;(longest diameter)/2; <bold>e</bold> The picture of Tumor entity; <bold>f</bold> Representative immunohistochemistry images of CD8-positive cells and quantitative data analysis; scale bar: 100&#8201;&#956;m; <bold>g</bold> The relative expression of immune factors (CCL5, CXCL10) and immune checkpoint (PD-L1) by qPCR; Unless otherwise specified above, one-way ANOVA was used for statistical analysis, while a two-tailed unpaired Student&#8217;s t-test was used to compare the two groups; Data are the mean&#8201;&#177; s.e.m; <italic toggle="yes">n</italic>&#8201;=&#8201;6 per group; *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1115" position="float" orientation="portrait" xlink:href="41522_2025_827_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec7"><title><italic toggle="yes">Debaryomyces hansenii</italic> influenced the efficacy of ICI in the mouse model</title><p id="Par14"><italic toggle="yes">Debaryomyces hansenii</italic> was found to be associated with the decreased effectiveness of ICIs in melanoma, as demonstrated by logistic regression analysis (Meta OR&#8201;=&#8201;0.69, Meta <italic toggle="yes">P</italic>&#8201;=&#8201;0.02) (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>). To further investigate the impact of <italic toggle="yes">Debaryomyces hansenii</italic> on ICI efficacy, we utilized a subcutaneous xenograft mouse model implanted with the melanoma cell line B16F10 (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>). In addition, we performed Internal Transcribed Spacer (ITS) sequencing of microbial DNA in mouse feces and discovered that the abundance of <italic toggle="yes">Debaryomyces hansenii</italic> was significantly higher in the daily gavage group compared to the control group (<italic toggle="yes">P</italic>&#8201;=&#8201;0.008, Fig. <xref rid="Fig6" ref-type="fig">6c</xref>). Following four intraperitoneal injections of either IgG2a or PD-1 mAb, we observed that <italic toggle="yes">Debaryomyces hansenii</italic> not only promoted tumor growth (<italic toggle="yes">P</italic>&#8201;=&#8201;0.03, Fig. <xref rid="Fig6" ref-type="fig">6d</xref>), but also reduced the effectiveness of PD-1 mAb treatment (Fig. <xref rid="Fig6" ref-type="fig">6e</xref>).</p><p id="Par15">Subsequently, we performed CD8 immunohistochemistry on mouse tumor tissues, revealing that a high abundance of <italic toggle="yes">Debaryomyces hansenii</italic> was associated with a reduced positive proportion of CD8+ T cells (<italic toggle="yes">P</italic>&#8201;=&#8201;0.012, Fig. <xref rid="Fig6" ref-type="fig">6f</xref>). Additionally, we observed decreased expression levels of CCL5 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.04), CXCL10 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.04), and PD-L1 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007) when comparing treatment with PD-1 mAb alone to treatment with PD-1 mAb combined with <italic toggle="yes">Debaryomyces hansenii</italic> (Fig. <xref rid="Fig6" ref-type="fig">6g</xref>).</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p id="Par16">A large number of studies have recently highlighted the significant role of gut bacteria and other host factors in the effectiveness of ICIs<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. However, the specific gut bacterial profiles associated with ICI efficacy differ across studies, influenced by geographic location, dietary practices, and other factors<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Furthermore, the predictive ability of gut bacteria for the effectiveness of ICIs was inadequate, although multi-cohort analyses were integrated to detect bacterial alterations<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Recent studies have shown that combining intestinal bacteria and fungi can enhance predictions regarding tumor response to ICIs. However, the majority of these investigations have concentrated on a specific cancer type or a broad array of cancers<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref></sup>. Herein, we focused on the role of intestinal fungi in the context of ICI treatment across different tumors. We analyzed metagenomic sequencing data of 976 samples from eight cohorts, covering three cancer types (melanoma, NSCLC, and RCC). This included 301 responders and 650 non-responders. Through a meta-analysis of these diverse cohorts, we present a comprehensive profile of gut microbiota&#8217;s response across various tumor types and identify species-level markers from different kingdoms that are associated with ICI efficacy.</p><p id="Par17">Herein, we identified 27 fungi in melanoma and 23 fungi in NSCLC associated with immunotherapy across a multi-cohort. Notably, most of them are plant pathogenic or involved in food fermentation fungi, and their role in mice or humans has been infrequently documented. Numerous investigations have demonstrated that intestinal fungi can significantly influence the host&#8217;s physiological and pathological conditions<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>, and our findings may guide future investigation in this field. One notable fungus identified in our analysis is <italic toggle="yes">Aspergillus avenaceus</italic>, which has the potential to enhance the effectiveness of ICIs in melanoma treatment. This fungus produces avenaciolide, a compound known for its antifungal and antibacterial effect, which also inhibits peptidoglycan biosynthesis in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic><sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. This suggests that <italic toggle="yes">Aspergillus avenaceus</italic> may play a role by influencing the growth of other microbes. The main components of the fungal cell wall include mannan or &#946;-glucan, which can be recognized by the pattern recognition receptors of immune cells, like natural killer T cells, dendritic cells, and macrophages, to induce an immune response against fungal infection<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. <italic toggle="yes">Aspergillus sydowii</italic> induces the expression of the CARD9 signaling pathway in host cells through &#946;-glucan binding to Dectin-1 in the cell wall, thereby inhibiting the killing ability of CD8+ T cells and ultimately promoting the development of lung cancer<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. <italic toggle="yes">Malassezia globosa</italic> is strongly associated with the high expression of PD-L1 in patients with gastric cancer<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and can accelerate the development of pancreatic cancer by stimulating the mannose-binding lectin-complement C3 pathway<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. It&#8217;s also worthwhile to look into whether <italic toggle="yes">Malassezia globosa</italic> and other fungi have comparable effects in the treatment with ICIs. Furthermore, related research has shown that certain fungus species alter immune checkpoint expressions during infection. For example, <italic toggle="yes">Candida albicans</italic> escapes the killing of natural killer T cells by binding to the checkpoint receptor TIGIT with lectin- like sequence protein<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. PD-L1, a common immune checkpoint, is highly abundant in phagosomes that contain yeast, such as <italic toggle="yes">Saccharomyces cerevisiae</italic>, and can directly bind to the yeast surface ribosomal protein Rpl20b, controlling the inflammatory response of phagocytes and the release of cytokines like IL-10<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. <italic toggle="yes">Candida auris</italic> infection causes upregulation of the PD-1/PD-L1 pathway in mice, suggesting the potential to improve the efficacy of immune checkpoint blocking therapy<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. In short, we cannot ignore the important role of intestinal fungi and their metabolites in intestinal immunity, nor can we ignore that they may change the expression of immune checkpoints and then affect the efficacy of ICIs in the treatment of tumors.</p><p id="Par18">The dynamics and resilience of the entire community are regulated by the gut microbiome, an ecosystem made up of intricate microbial interactions<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The development and course of disease are influenced by interactions between fungi and bacteria<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Current studies have confirmed that intestinal bacteria and fungi can interact through the secretion of metabolites to affect colonization and growth<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>, biofilm formation<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and other processes. While antibiotic-mediated bacterial depletion lowers reactivity and is linked to the expansion of symbiotic fungi, antifungal-mediated fungal depletion increases the effectiveness of radiation therapy, indicating that gut bacteria and fungi collaborate to maintain antitumor immunity<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Here, we constructed intestinal bacteria-fungus interaction networks in melanoma and NSCLC. In melanoma patients, we observed that both intra-kingdom (bacteria-bacteria, fungi-fungi) and inter-kingdom (bacteria-fungi) correlations were stronger among responders compared to non-responders, a trend consistent with earlier reports by Huang et al.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Conversely, in NSCLC, we found a reversal of this trend, likely due to the low microbial abundance influenced by sequencing depth and the limited percentage of responders (20% of the total samples) on the other. Interestingly, most associations in both melanoma and NSCLC were positive, with a slightly higher proportion observed among responders. Overall, this also implies that we should modulate the interaction between bacteria and fungi through the use of antibiotics, probiotics, antifungal medications, or dietary strategies, which will enable us to successfully increase the efficacy of ICIs. Just as probiotic bacteria like <italic toggle="yes">Bifidobacterium bifidum</italic> (favorable for response to ICI in melanoma in our study) can prevent intestinal fungi from colonizing by generating lipopeptides<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The probiotic fungi, such as <italic toggle="yes">Saccharomyces boulardii</italic>, can enhance humoral immunity and innate immunity, improve the integrity of intestinal epithelium, and restructure the composition of the gut microbiota<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par19">It has been suggested that enterotypes can efficiently stratify populations, summarize the traits of the human gut microbiome, and give a general picture of the variations in gut microbiome composition among individuals<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. In this study, we identified three fungal enterotypes: <italic toggle="yes">Asper_high</italic>, <italic toggle="yes">Sacc_type</italic>, and <italic toggle="yes">Asper_low</italic>. Compared with the classification by Lai et al.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, we lacked enterotypes characterized by <italic toggle="yes">Candida</italic>, which may be due to geographical location. Most of our samples were from Europe, where the flora was characterized by the expansion of <italic toggle="yes">Saccharomyces</italic> and <italic toggle="yes">Penicillium</italic> but the consumption of <italic toggle="yes">Candida</italic><sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. We found that patients with the <italic toggle="yes">Asper_high</italic> had a higher proportion of response to ICI treatment, followed by those with the <italic toggle="yes">Sacc_type</italic>, which was a rare perspective on the association between fungal enterotypes and ICI efficacy. The majority of current research centers around the possible connection between bacterial enterotypes and illness or drug response<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>, which also serves as a theoretical guide for investigations involving fecal microbiota transplantation (FMT)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. An aging-enriched enterotype with abundant <italic toggle="yes">Bacteroides</italic> has been linked to a positive response to ICI therapy<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, which is consistent with the characteristics of bacterial enterotypes in this study. Thus, it also offers a study approach for boosting the effectiveness of ICIs through FMT and improving prognosis dependent on the fungal enterotypes. Additionally, we found that fungal enterotypes differ across cohorts and cancer types, which may be influenced by sequencing platforms and geographic locations.</p><p id="Par20">Considering the culturability and safety of fungi in the laboratory, we selected the top 10 associated <italic toggle="yes">Debaryomyces hansenii</italic> with response to ICIs in melanoma for in vivo validation. <italic toggle="yes">Debaryomyces hansenii</italic> is an uncommon human fungal pathogen that is frequently present in dairy products, particularly processed meats and cheeses<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, but it is frequently detected in stool metagenomic sequencing<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. At present, the relevant literature shows that <italic toggle="yes">Debaryomyces hansenii</italic> not only can enrich the damaged part of the intestine and hinder intestinal repair<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, but also is associated with autoimmune diseases<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. However, its impact on tumor immunotherapy remains unclear. It appears to decrease the effectiveness of ICIs in treating melanoma by lowering the percentage of CD8+ T cells, according to both our association findings and in vivo confirmation in mice. Nevertheless, further investigation is needed to elucidate the underlying mechanisms of this interaction.</p><p id="Par21">The study had some limitations. First, the small number of cohorts for NSCLC and RCC and the fact that most of the samples were sourced from France or Canada limited the assessment of the impact of geographic differences on gut microbiota and affected the accuracy of the results, with some heterogeneity present. The microbial signatures in various tumors fluctuate greatly, and there are comparatively few common microbial signatures because of the imbalance in cohort numbers, as well as variations in sequencing platforms and depths. Additionally, this causes some discrepancies in the findings of enterotypes and microbial interaction analyses between melanoma and NSCLC. It is impossible to rule out that the fraction of responders, sequencing depth, and cohort size had an impact on this. Second, because fungal DNA is difficult to extract and its abundance in the gut is low, more precise sequencing methods and sequencing depth are required. The sequencing depth of some cohorts in this study was low, resulting in sparse fungal abundance, and the obtained association results were biased to a certain extent. Third, some of the fungi associated with the efficacy of ICIs are difficult to culture or have a certain risk, and it cannot even be determined whether they are contaminated strains. Therefore, its role cannot be verified. Next, it is impossible to tell whether the low-abundance fungi are actual biological signals in the intestinal fungus or just technical noise because this study does not have blank control or negative control samples. Finally, it is currently unknown how exactly intestinal fungi, such as <italic toggle="yes">Debaryomyces hansenii</italic>, impact the efficacy of ICIs; further research is required to elucidate this mechanism.</p><p id="Par22">Overall, we conducted a meta-analysis to identify microbial signatures that influence the effectiveness of ICIs across various cancers using fecal metagenomic sequencing data. We also validated the role of <italic toggle="yes">Debaryomyces hansenii</italic> in melanoma immunotherapy through functional validation in vivo experiments. Furthermore, we examined the connection between fungal enterotypes and ICI treatment, as well as the interaction between microbial kingdoms. Altogether, our findings indicate that we should not overlook the role of intestinal fungi in tumor immunotherapy but rather highlight the crucial role of multi-kingdom microbes in ICI therapy, thereby providing insights for improving tumor immune efficacy and providing a reference for further studies on intestinal fungi.</p></sec><sec id="Sec9"><title>Methods</title><sec id="Sec10"><title>Collection of metagenomic files and metadata from patients treated with ICIs</title><p id="Par23">The National Center for Biotechnology Information (NCBI) was searched for studies on human fecal shotgun metagenomic sequencing related to ICIs. Our analysis included data from 1161 patients across eight cohorts, comprising 489 patients with melanoma, 571 patients with NSCLC, and 101 patients with RCC. Metagenomic sequencing data were downloaded from the European Nucleotide Archive (ENA) for the following projects: PRJEB22863 for RoutyB_2018<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, PRJEB43119 for LeeKA_2022<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, PRJNA397906 for FrankelAE_2017<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, PRJNA399742 for MatsonV_2018<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, PRJNA541981 for PetersBA_2020<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, PRJNA1023797 for DerosaL_2024<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, PRJNA762360 for McCullochJA_2022<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, and PRJNA770295 for SpencerCN_2021<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Additionally, metadata were manually curated from the respective published studies.</p><p id="Par24">Given the clinical tumor radiological data and the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, the following classifications of response to ICIs are made in clinical practice.: complete response (CR), partial response (PR), stable disease (SD), and progressing disease (PD). In our study, responders (R) were classified as either PR or CR, while non-responders (NR) included all other categories. We also defined additional metrics, including PFS, OS, PFS6, and PFS12, which align with the original published studies. These metrics have been thoroughly verified for consistency.</p></sec><sec id="Sec11"><title>Sequence preprocessing and taxonomic profiling</title><p id="Par25">The KneadData v.0.6.1 tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://huttenhower.sph.harvard.edu/kneaddata">http://huttenhower.sph.harvard.edu/kneaddata</ext-link>) was used to process our data, ensuring the microbial reads were of high quality and free from contaminants. Low-quality reads were filtered out using Trimmomatic. The remaining reads were mapped to mammalian genomes, bacterial plasmids, complete plastomes, and UniVec sequences with Bowtie2 v.2.3.5.1<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. This mapping process allowed us to isolate microbial sequences by removing those associated with host or laboratory origins.</p><p id="Par26">For taxonomic classification of bacteria, archaea, fungi, and viruses, we employed Kraken2 v.2.1.2<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, an advanced metagenomic taxonomy classifier. A custom database consisting of 38,278 bacterial reference genomes, 580 archaeal reference genomes, and 14,972 viral reference genomes from the NCBI RefSeq database (downloaded on September 15, 2023), along with 1919 fungal reference genomes from the NCBI RefSeq database, FungiDB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://fungidb.org">http://fungidb.org</ext-link>, v65), and Ensemble (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://fungi.ensembl.org">http://fungi.ensembl.org</ext-link>, v57), was built. To estimate taxonomic abundance, especially at the species and genus level, Bracken (v2.8) was used based on the results from Kraken2<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. The read counts for each species were then converted into relative abundance. Pearson correlation analysis was used to analyze the correlation between sequencing depth and fungal reads.</p></sec><sec id="Sec12"><title>Sample filtration</title><p id="Par27">To ensure data consistency and quality, we conduct a sample filter process based on the data features of this study and the guidelines established by Lin et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Firstly, we removed the samples with low alignment read counts (&lt;1 million), which were attributed to low sequencing depth and host contamination. Additionally, given that the genetic material of fungi is less than 1% of the total microbial material in the intestine<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>, and the extremely low fungal reads make the abundance overly sparse, we retained samples where the total microbial read counts showed a ratio of fungal reads between 0.01% and 1%. To assess potential bias in the sample filtering process, we employed the &#967;<sup>2</sup> test, confirming that samples were evenly distributed among different groups.</p></sec><sec id="Sec13"><title>Microbial diversity analysis</title><p id="Par28">The metrics of &#945;-diversity of each sample, specifically the Shannon index, were calculated using the R package &#8220;otusummary&#8221;. The Wilcoxon test was utilized to assess differences in alpha diversity between responders and non-responders, taking into account stratification variables such as cohort, gender, age, and BMI. Age and BMI were initially continuous variables, but for the convenience of analysis and the completeness of clinical information collection, we divided age into the old (&#8805;60 years old) and the young (&lt;60 years old). BMI was classified as lean (&lt;25), overweight (25&#8211;30), and obese (&gt;30) according to conventional cut-offs for obesity. Likewise, &#946;-diversity was evaluated using the Bray&#8211;Curtis distance. A permutational multivariate analysis of variance (PERMANOVA) was conducted with 999 permutations to examine the differences in the microbial community between responders and non-responders, adjusted by cohort, age, and gender.</p></sec><sec id="Sec14"><title>Identification of microbial features associated with efficacy of ICIs</title><p id="Par29">To standardize the study, batch effect correction of microbial relative abundance was carried out using the MMUPHin approach<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, given the sparse attributes of microbial data and heterogeneity among cohorts. Fungal species with a relative abundance of &gt;0.1% and mapped in at least 10% of samples were included in subsequent association analyses. The criterion for the relative abundance of bacterial species was set at 0.001% to accommodate the significant variability in the number and abundance of gut fungal and bacterial species observed. The relative abundance data of microbial species were ranked from large to small, with the first 33% of samples classified as high group, the last 33% as low group, and the remaining samples as middle group, and multivariate logistic regression or Cox regression was employed to investigate their associations with the response to ICIs, PFS6, PFS12, OS, and PFS. Meanwhile, in the cohorts of FrankelAE_2017 and RoutyB_2018, we adjusted for the effects of covariates such as gender, age, and read-depth. In the cohort of MatsonV_2018, gender and read-depth corrections were employed. For the remaining cohorts, gender, age, BMI, and read-depth were used for correction. A meta-analysis was carried out to identify the associated microbial signatures, applying a <italic toggle="yes">p</italic>-value threshold of greater than 0.05 for heterogeneity (<italic toggle="yes">het P</italic>) and less than 0.05 for significance in the meta-analysis (Meta <italic toggle="yes">P</italic>).</p></sec><sec id="Sec15"><title>Construction of bacteria-fungus interaction network</title><p id="Par30">Given that some marginal significantly correlated signatures may be involved in the interaction between bacteria and fungi, we chose to the species with Meta <italic toggle="yes">P</italic> less than 0.1 to constructed the interaction network by calculating the Spearman correlation coefficient in the different groups (responders vs. non-responders). The <italic toggle="yes">p</italic>-value was corrected for multiple comparisons using the &#8220;BH&#8221; method to obtain the FDR. When FDR is less than 0.05 and the absolute value of the correlation coefficient is greater than 0.2, it is considered that there is a correlation between the microbial abundances. Particularly, the empirical <italic toggle="yes">p</italic>-value with less than 0.05 was utilized to assess whether the correlation of microbial pairs was different between responders and non-responders using permutation testing in the R package &#8220;DCGA&#8221;<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. The resulting network was visualized with Gephi v0.10.1.</p></sec><sec id="Sec16"><title>Identification of microbial enterotype</title><p id="Par31">The samples were organized into enterotypes with partitioning around medoid (PAM) based on the Bray&#8211;Curtis distance estimated at the genus level. This analysis focused on genera with an abundance greater than 0.1% in at least 40% of the samples. The optimal number of enterotypes was determined using Silhouette scores, with the maximum average relative abundance representing the defining characteristic of each enterotype. To test the association between enterotypes and response to ICIs, we employed the &#967;<sup>2</sup> test or two-sided test for Fisher&#8217;s Exact test.</p></sec><sec id="Sec17"><title>Validation of characteristic fungi in mice</title><p id="Par32"><italic toggle="yes">Debaryomyces hansenii</italic> NRRL Y-833 was obtained from the China General Microbiological Culture Collection Center (depository number: CGMCC 2.493) and cultured on Sabouraud Dextrose Broth (SDB) at 28&#8201;&#176;C for 36&#8201;h by oscillating. The count was determined by the dilution-coated plate method.</p><p id="Par33">Six-week-old female conventional C57BL/6 mice were housed in an air-filtered and pathogen-free condition. After one week of acclimation, mice were randomly divided into four groups based on body weight with 6 mice in each group. Murine melanoma B16F10 cells were resuspended in phosphate-buffered saline (PBS; 5 &#215;10<sup>5</sup> cells) and injected into the right flank of each mouse. Intragastric administration of 200&#8201;&#956;L of <italic toggle="yes">Debaryomyces hansenii</italic> (5 &#215;10<sup>8</sup> colony-forming units per mL) or PBS one week in advance until the end of the experiment. One week after tumor inoculation, each mouse was intraperitoneally injected with 200&#8201;&#956;g of anti-mouse PD-1 mAb (BioXCell, BE0146, USA) or IgG2a (BioXCell, BE0089, USA) every 3 days for a total of 4 times. Tumor volume was measured every two days using vernier calipers. At the end of the experiment, fungi in the feces of mice were detected by ITS sequencing to determine the abundance of <italic toggle="yes">Debaryomyces hansenii</italic>. All animal experiments were approved by the Experimental Animal Ethics Review Committee of Xiangya Hospital, Central South University (No. 202407132). All mice were anesthetized by inhalation of isoflurane (RWD, R5102210, China) and euthanized by cervical dislocation.</p></sec><sec id="Sec18"><title>Immunohistochemistry</title><p id="Par34">For IHC, tissue sections were incubated overnight at 4&#8201;&#176;C with primary antibodies overnight (CD8, Abcam, code #ab209775). Following this, they were treated with a secondary antibody (Abcam, code #ab205718) conjugated to horseradish peroxidase (HRP) at room temperature for 45&#8201;min. The sections were then counterstained with hematoxylin. Statistical analysis of the results was performed using ImageJ.</p></sec><sec id="Sec19"><title>RNA isolation and real-time quantitative PCR</title><p id="Par35">Total RNA was extracted from tumor tissues using Trizol (Taraka, code #9109), and the quality and concentration of RNA were measured using the Nanodrop 2000 (ThermoFisher Scientific, Massachusetts, USA). 1&#8201;&#956;g of total RNA was reverse transcribed to determine relative mRNA expression with PrimeScript<sup><italic toggle="yes">TM</italic></sup> RT reagent kit (Takara). Quantitative PCR was performed using TB qPCR Premix (Takara #639676) on an Eppendorf Mastercycler (Eppendorf), utilizing the following primers:</p><p id="Par36"><italic toggle="yes">&#946;-actin</italic>: Forward: (5&#8217;-ATATCGCTGCGCTGGTCGT-3&#8217;, Reverse: (5&#8217;-CCTTCTGACCCATTCCCACC-3&#8217;);</p><p id="Par37"><italic toggle="yes">CCL5</italic>: Forward: (5&#8217;-GCTGCTTTGCCTACCTCTCC-3&#8217;), Reverse: (5&#8217;-TCGAGTGACAAACACGACTGC-3&#8217;);</p><p id="Par38"><italic toggle="yes">CXCL10</italic>: Forward: (5&#8217;-TCCCTATGGCCCTCATTCTCA-3&#8217;), Reverse: (5&#8217;-CTTACTGACTGGCATGAGGATCA-3&#8217;);</p><p id="Par39"><italic toggle="yes">PDL1</italic>: Forward: (5&#8217;-GCTCCAAAGGACTTGTACGTG-3&#8217;), Reverse: (5&#8217;-TGATCTGAAGGGCAGCATTTC-3&#8217;).</p><p id="Par40">For quantification of immune-related genes in tumor tissue, relative abundance was calculated by the &#916;&#916;Ct method and normalized to the amount of <italic toggle="yes">&#946;-actin</italic>.</p></sec><sec id="Sec20"><title>Statistical analysis</title><p id="Par41">Multivariate logistic regression was used to examine the association between binary categorical variables (response to ICIs, PFS6, and PFS12) and microbial abundance. Multivariate Cox regression models were used to determine the association between outcomes (OS, PFS) and microbial abundance. Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was applied for comparisons. The relationship between enterotypes and response to ICIs was determined by the &#967;<sup>2</sup> test or two-sided test for Fisher&#8217;s Exact test. One-way analysis of variance (ANOVA) for the entire analysis with Tukey&#8217;s post hoc test for multiple comparisons was used to analyze the results of multiple groups, while a two-tailed unpaired Student&#8217;s <italic toggle="yes">t</italic> test was used to compare the two groups in animal experiments. A <italic toggle="yes">p</italic>-value of less than 0.05 was considered statistically significant, and two-sided tests were used unless otherwise indicated. Furthermore, we also employed the Benjamini&#8211;Hochberg (BH) method for multiple hypothesis correction to obtain the corrected <italic toggle="yes">p</italic>-values. All analyses were performed on R 4.3.3 and GraphPad Prism 10.1.2.</p></sec></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41522_2025_827_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41522_2025_827_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Author Checklist_E10.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41522_2025_827_MOESM3_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41522-025-00827-2.</p></sec><ack><title>Acknowledgements</title><p>This study was partly supported by the National Key Research and Development Program 2021YFA1301200, the National Scientific Foundation of China (No. 82474022, 31801121, 82373961) and the Hunan Provincial Science and Technology Innovation Plan Project (2022RC1022). The authors acknowledge the authors from published studies to share their metagenomics sequencing data of immunotherapy trials and are grateful for resources from the High-Performance Computing Center of Central South University and The Bioinformatics Center, Xiangya Hospital, Central South University.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>R.L. conceived and supervised the study and contributed to the study design, Y.Z. contributed to the data collection and provided assistance for parallel computing. L.Z. performed statistical analysis, conducted the in-vivo experiments, interpreted and drafted the manuscript. D.D.Z. assisted mouse experiment design and tumor cell culture. J.F., Z.J.L., X.L.S., and R.M.Y. participated in mouse experiments. W.Z. and Y.C.G. offered suggestions for the experimental design. H.H.Z provided the experimental platform and equipment. All authors contributed to critical revision of the final manuscript. R.L. and Y.Z. approved the final version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The raw metagenomic data are available in the SRA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra">https://www.ncbi.nlm.nih.gov/sra</ext-link>) and European Nucleotide Archive (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/">https://www.ebi.ac.uk/ena/</ext-link>) under accession nos. PRJEB22863, PRJEB43119, PRJNA397906, PRJNA399742, PRJNA541981, PRJNA1023797, PRJNA762360 and PRJNA770295.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>R scripts demonstrating how to reproduce all findings shown in the main figures are available via <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/liuronghyw/ICI_fungi">https://github.com/liuronghyw/ICI_fungi</ext-link>.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlino</surname><given-names>MS</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Long</surname><given-names>GV</given-names></name></person-group><article-title>Immune checkpoint inhibitors in melanoma</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1002</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01206-X</pub-id><pub-id pub-id-type="pmid">34509219</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Carlino, M. S., Larkin, J. &amp; Long, G. V. Immune checkpoint inhibitors in melanoma. <italic toggle="yes">Lancet</italic><bold>398</bold>, 1002&#8211;1014 (2021).<pub-id pub-id-type="pmid">34509219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01206-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dall&#8217;Olio</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Tumour burden and efficacy of immune-checkpoint inhibitors</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>75</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00564-3</pub-id><pub-id pub-id-type="pmid">34642484</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dall&#8217;Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>19</bold>, 75&#8211;90 (2022).<pub-id pub-id-type="pmid">34642484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00564-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morad</surname><given-names>G</given-names></name><name name-style="western"><surname>Helmink</surname><given-names>BA</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>JA</given-names></name></person-group><article-title>Hallmarks of response, resistance, and toxicity to immune checkpoint blockade</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>5309</fpage><lpage>5337</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.020</pub-id><pub-id pub-id-type="pmid">34624224</pub-id><pub-id pub-id-type="pmcid">PMC8767569</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Morad, G., Helmink, B. A., Sharma, P. &amp; Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <italic toggle="yes">Cell</italic><bold>184</bold>, 5309&#8211;5337 (2021).<pub-id pub-id-type="pmid">34624224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.09.020</pub-id><pub-id pub-id-type="pmcid">PMC8767569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies</article-title><source>J. Hematol. Oncol.</source><year>2022</year><volume>15</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01273-9</pub-id><pub-id pub-id-type="pmid">35488243</pub-id><pub-id pub-id-type="pmcid">PMC9052532</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. <italic toggle="yes">J. Hematol. Oncol.</italic><bold>15</bold>, 47 (2022).<pub-id pub-id-type="pmid">35488243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01273-9</pub-id><pub-id pub-id-type="pmcid">PMC9052532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01695-5</pub-id><pub-id pub-id-type="pmid">35228751</pub-id><pub-id pub-id-type="pmcid">PMC8938272</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 535&#8211;544 (2022).<pub-id pub-id-type="pmid">35228751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01695-5</pub-id><pub-id pub-id-type="pmcid">PMC8938272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. <italic toggle="yes">Cell</italic><bold>187</bold>10.1016/j.cell.2024.05.029 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.05.029</pub-id><pub-id pub-id-type="pmid">38906102</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Wu, X. Q. et al. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. <italic toggle="yes">Cell Rep. Med.</italic> 101900 10.1016/j.xcrm.2024.101900 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2024.101900</pub-id><pub-id pub-id-type="pmcid">PMC11866522</pub-id><pub-id pub-id-type="pmid">39798567</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saftien</surname><given-names>A</given-names></name><name name-style="western"><surname>Puschhof</surname><given-names>J</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E</given-names></name></person-group><article-title>Fungi and cancer</article-title><source>Gut</source><year>2023</year><volume>72</volume><fpage>1410</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2022-327952</pub-id><pub-id pub-id-type="pmid">37147013</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Saftien, A., Puschhof, J. &amp; Elinav, E. Fungi and cancer. <italic toggle="yes">Gut</italic><bold>72</bold>, 1410&#8211;1425 (2023).<pub-id pub-id-type="pmid">37147013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2022-327952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Alam, A. et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. <italic toggle="yes">Cancer Cell</italic><bold>40</bold>10.1016/j.ccell.2022.01.003 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2022.01.003</pub-id><pub-id pub-id-type="pmcid">PMC8847236</pub-id><pub-id pub-id-type="pmid">35120601</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Aschenbrenner</surname><given-names>D</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JY</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>T</given-names></name></person-group><article-title>The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e969</fpage><lpage>e983</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00203-8</pub-id><pub-id pub-id-type="pmid">36182668</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhang, F., Aschenbrenner, D., Yoo, J. Y. &amp; Zuo, T. The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. <italic toggle="yes">Lancet Microbe</italic><bold>3</bold>, e969&#8211;e983 (2022).<pub-id pub-id-type="pmid">36182668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(22)00203-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Protocol to identify fungal profile from fecal metagenomes in cancer patients prior to immunotherapy</article-title><source>STAR Protoc.</source><year>2024</year><volume>5</volume><fpage>102847</fpage><pub-id pub-id-type="doi">10.1016/j.xpro.2024.102847</pub-id><pub-id pub-id-type="pmid">38277270</pub-id><pub-id pub-id-type="pmcid">PMC10837094</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Huang, X., Li, L. &amp; Chen, H. Protocol to identify fungal profile from fecal metagenomes in cancer patients prior to immunotherapy. <italic toggle="yes">STAR Protoc.</italic><bold>5</bold>, 102847 (2024).<pub-id pub-id-type="pmid">38277270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xpro.2024.102847</pub-id><pub-id pub-id-type="pmcid">PMC10837094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses</article-title><source>Gastroenterology</source><year>2022</year><volume>163</volume><fpage>908</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.06.038</pub-id><pub-id pub-id-type="pmid">35724733</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lin, Y. et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. <italic toggle="yes">Gastroenterology</italic><bold>163</bold>, 908&#8211;921 (2022).<pub-id pub-id-type="pmid">35724733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2022.06.038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N-N</given-names></name><etal/></person-group><article-title>Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts</article-title><source>Nat. Microbiol</source><year>2022</year><volume>7</volume><fpage>238</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-01030-7</pub-id><pub-id pub-id-type="pmid">35087227</pub-id><pub-id pub-id-type="pmcid">PMC8813618</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Liu, N.-N. et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. <italic toggle="yes">Nat. Microbiol</italic><bold>7</bold>, 238&#8211;250 (2022).<pub-id pub-id-type="pmid">35087227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-021-01030-7</pub-id><pub-id pub-id-type="pmcid">PMC8813618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Huang, X. et al. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. <italic toggle="yes">Cell Host Microbe</italic><bold>31</bold>10.1016/j.chom.2023.10.005 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2023.10.005</pub-id><pub-id pub-id-type="pmid">37944495</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Characterizing and measuring bias in sequence data</article-title><source>Genome Biol.</source><year>2013</year><volume>14</volume><fpage>R51</fpage><pub-id pub-id-type="doi">10.1186/gb-2013-14-5-r51</pub-id><pub-id pub-id-type="pmid">23718773</pub-id><pub-id pub-id-type="pmcid">PMC4053816</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ross, M. G. et al. Characterizing and measuring bias in sequence data. <italic toggle="yes">Genome Biol.</italic><bold>14</bold>, R51 (2013).<pub-id pub-id-type="pmid">23718773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2013-14-5-r51</pub-id><pub-id pub-id-type="pmcid">PMC4053816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothschild</surname><given-names>D</given-names></name><etal/></person-group><article-title>Environment dominates over host genetics in shaping human gut microbiota</article-title><source>Nature</source><year>2018</year><volume>555</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/nature25973</pub-id><pub-id pub-id-type="pmid">29489753</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. <italic toggle="yes">Nature</italic><bold>555</bold>, 210&#8211;215 (2018).<pub-id pub-id-type="pmid">29489753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature25973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Mycobiome in the gut: a multiperspective review</article-title><source>Mediators Inflamm.</source><year>2020</year><volume>2020</volume><fpage>9560684</fpage><pub-id pub-id-type="doi">10.1155/2020/9560684</pub-id><pub-id pub-id-type="pmid">32322167</pub-id><pub-id pub-id-type="pmcid">PMC7160717</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Chin, V. K. et al. Mycobiome in the gut: a multiperspective review. <italic toggle="yes">Mediators Inflamm.</italic><bold>2020</bold>, 9560684 (2020).<pub-id pub-id-type="pmid">32322167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/9560684</pub-id><pub-id pub-id-type="pmcid">PMC7160717</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Enterotypes of the human gut microbiome</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nature09944</pub-id><pub-id pub-id-type="pmid">21508958</pub-id><pub-id pub-id-type="pmcid">PMC3728647</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Arumugam, M. et al. Enterotypes of the human gut microbiome. <italic toggle="yes">Nature</italic><bold>473</bold>, 174&#8211;180 (2011).<pub-id pub-id-type="pmid">21508958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09944</pub-id><pub-id pub-id-type="pmcid">PMC3728647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayase</surname><given-names>E</given-names></name><name name-style="western"><surname>Jenq</surname><given-names>RR</given-names></name></person-group><article-title>Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer</article-title><source>Genome Med.</source><year>2021</year><volume>13</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00923-w</pub-id><pub-id pub-id-type="pmid">34162429</pub-id><pub-id pub-id-type="pmcid">PMC8220726</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hayase, E. &amp; Jenq, R. R. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. <italic toggle="yes">Genome Med.</italic><bold>13</bold>, 107 (2021).<pub-id pub-id-type="pmid">34162429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-021-00923-w</pub-id><pub-id pub-id-type="pmcid">PMC8220726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Limeta, A., Ji, B., Levin, M., Gatto, F. &amp; Nielsen, J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. <italic toggle="yes">JCI Insight</italic><bold>5</bold>10.1172/jci.insight.140940 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.140940</pub-id><pub-id pub-id-type="pmcid">PMC7714408</pub-id><pub-id pub-id-type="pmid">33268597</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler</surname><given-names>ML</given-names></name><name name-style="western"><surname>Limon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Underhill</surname><given-names>DM</given-names></name></person-group><article-title>Immunity to commensal fungi: detente and disease</article-title><source>Annu. Rev. Pathol.</source><year>2017</year><volume>12</volume><fpage>359</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-052016-100342</pub-id><pub-id pub-id-type="pmid">28068483</pub-id><pub-id pub-id-type="pmcid">PMC6573037</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wheeler, M. L., Limon, J. J. &amp; Underhill, D. M. Immunity to commensal fungi: detente and disease. <italic toggle="yes">Annu. Rev. Pathol.</italic><bold>12</bold>, 359&#8211;385 (2017).<pub-id pub-id-type="pmid">28068483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathol-052016-100342</pub-id><pub-id pub-id-type="pmcid">PMC6573037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C-M</given-names></name><etal/></person-group><article-title>Avenaciolides: potential MurA-targeted inhibitors against peptidoglycan biosynthesis in methicillin-resistant Staphylococcus aureus (MRSA)</article-title><source>J. Am. Chem. Soc.</source><year>2015</year><volume>137</volume><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1021/ja510375f</pub-id><pub-id pub-id-type="pmid">25521652</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chang, C.-M. et al. Avenaciolides: potential MurA-targeted inhibitors against peptidoglycan biosynthesis in methicillin-resistant Staphylococcus aureus (MRSA). <italic toggle="yes">J. Am. Chem. Soc.</italic><bold>137</bold>, 267&#8211;275 (2015).<pub-id pub-id-type="pmid">25521652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja510375f</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castelo-Branco</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Synthesis, characterization, absolute structural determination and antifungal activity of a new chlorinated aromatic avenaciolide analogue</article-title><source>Pest Manag. Sci.</source><year>2009</year><volume>65</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/ps.1640</pub-id><pub-id pub-id-type="pmid">18785221</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Castelo-Branco, P. A. et al. Synthesis, characterization, absolute structural determination and antifungal activity of a new chlorinated aromatic avenaciolide analogue. <italic toggle="yes">Pest Manag. Sci.</italic><bold>65</bold>, 34&#8211;40 (2009).<pub-id pub-id-type="pmid">18785221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ps.1640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Underhill</surname><given-names>DM</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>E</given-names></name></person-group><article-title>Immune interactions with pathogenic and commensal fungi: a two-way street</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>845</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.10.023</pub-id><pub-id pub-id-type="pmid">26588778</pub-id><pub-id pub-id-type="pmcid">PMC4865256</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Underhill, D. M. &amp; Pearlman, E. Immune interactions with pathogenic and commensal fungi: a two-way street. <italic toggle="yes">Immunity</italic><bold>43</bold>, 845&#8211;858 (2015).<pub-id pub-id-type="pmid">26588778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2015.10.023</pub-id><pub-id pub-id-type="pmcid">PMC4865256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Liu, N.-N. et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. <italic toggle="yes">Cancer Cell</italic><bold>41</bold>10.1016/j.ccell.2023.08.012 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2023.08.012</pub-id><pub-id pub-id-type="pmid">37738973</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification of Malassezia globosa as a gastric fungus associated with PD-L1 expression and overall survival of patients with gastric cancer</article-title><source>J. Immunol. Res.</source><year>2022</year><volume>2022</volume><fpage>2430759</fpage><pub-id pub-id-type="doi">10.1155/2022/2430759</pub-id><pub-id pub-id-type="pmid">36405009</pub-id><pub-id pub-id-type="pmcid">PMC9669766</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhang, Z. et al. Identification of Malassezia globosa as a gastric fungus associated with PD-L1 expression and overall survival of patients with gastric cancer. <italic toggle="yes">J. Immunol. Res.</italic><bold>2022</bold>, 2430759 (2022).<pub-id pub-id-type="pmid">36405009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/2430759</pub-id><pub-id pub-id-type="pmcid">PMC9669766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aykut</surname><given-names>B</given-names></name><etal/></person-group><article-title>The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1608-2</pub-id><pub-id pub-id-type="pmid">31578522</pub-id><pub-id pub-id-type="pmcid">PMC6858566</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Aykut, B. et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. <italic toggle="yes">Nature</italic><bold>574</bold>, 264&#8211;267 (2019).<pub-id pub-id-type="pmid">31578522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1608-2</pub-id><pub-id pub-id-type="pmcid">PMC6858566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charpak-Amikam</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>2463</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30087-z</pub-id><pub-id pub-id-type="pmid">35513379</pub-id><pub-id pub-id-type="pmcid">PMC9072312</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Charpak-Amikam, Y. et al. Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 2463 (2022).<pub-id pub-id-type="pmid">35513379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-30087-z</pub-id><pub-id pub-id-type="pmcid">PMC9072312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor</article-title><source>Nature</source><year>2024</year><volume>630</volume><fpage>736</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07499-6</pub-id><pub-id pub-id-type="pmid">38839956</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li, K. et al. Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. <italic toggle="yes">Nature</italic><bold>630</bold>, 736&#8211;743 (2024).<pub-id pub-id-type="pmid">38839956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07499-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wurster</surname><given-names>S</given-names></name><name name-style="western"><surname>Albert</surname><given-names>ND</given-names></name><name name-style="western"><surname>Kontoyiannis</surname><given-names>DP</given-names></name></person-group><article-title>Candida auris bloodstream infection induces upregulation of the PD-1/PD-L1 immune checkpoint pathway in an immunocompetent mouse model</article-title><source>mSphere</source><year>2022</year><volume>7</volume><fpage>e0081721</fpage><pub-id pub-id-type="doi">10.1128/msphere.00817-21</pub-id><pub-id pub-id-type="pmid">35224979</pub-id><pub-id pub-id-type="pmcid">PMC9044930</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wurster, S., Albert, N. D. &amp; Kontoyiannis, D. P. Candida auris bloodstream infection induces upregulation of the PD-1/PD-L1 immune checkpoint pathway in an immunocompetent mouse model. <italic toggle="yes">mSphere</italic><bold>7</bold>, e0081721 (2022).<pub-id pub-id-type="pmid">35224979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/msphere.00817-21</pub-id><pub-id pub-id-type="pmcid">PMC9044930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Kr&#252;ger, W., Vielreicher, S., Kapitan, M., Jacobsen, I. D. &amp; Niemiec, M. J. Fungal-bacterial interactions in health and disease. <italic toggle="yes">Pathogens</italic><bold>8</bold>10.3390/pathogens8020070 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens8020070</pub-id><pub-id pub-id-type="pmcid">PMC6630686</pub-id><pub-id pub-id-type="pmid">31117285</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kombrink</surname><given-names>A</given-names></name><etal/></person-group><article-title>Induction of antibacterial proteins and peptides in the coprophilous mushroom Coprinopsis cinerea in response to bacteria</article-title><source>ISME J.</source><year>2019</year><volume>13</volume><fpage>588</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41396-018-0293-8</pub-id><pub-id pub-id-type="pmid">30301946</pub-id><pub-id pub-id-type="pmcid">PMC6461984</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kombrink, A. et al. Induction of antibacterial proteins and peptides in the coprophilous mushroom Coprinopsis cinerea in response to bacteria. <italic toggle="yes">ISME J.</italic><bold>13</bold>, 588&#8211;602 (2019).<pub-id pub-id-type="pmid">30301946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41396-018-0293-8</pub-id><pub-id pub-id-type="pmcid">PMC6461984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Garc&#237;a, C. et al. The human gut microbial metabolome modulates fungal growth via the TOR signaling pathway. <italic toggle="yes">mSphere</italic><bold>2</bold>10.1128/mSphere.00555-17 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mSphere.00555-17</pub-id><pub-id pub-id-type="pmcid">PMC5729221</pub-id><pub-id pub-id-type="pmid">29242837</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Hoarau, G. et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn&#8217;s disease. <italic toggle="yes">mBio</italic><bold>7</bold>10.1128/mBio.01250-16 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01250-16</pub-id><pub-id pub-id-type="pmcid">PMC5030358</pub-id><pub-id pub-id-type="pmid">27651359</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Shiao, S. L. et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. <italic toggle="yes">Cancer Cell</italic><bold>39</bold>10.1016/j.ccell.2021.07.002 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2021.07.002</pub-id><pub-id pub-id-type="pmcid">PMC8830498</pub-id><pub-id pub-id-type="pmid">34329585</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>S</given-names></name><name name-style="western"><surname>Mansell</surname><given-names>TJ</given-names></name></person-group><article-title>Yeasts as probiotics: mechanisms, outcomes, and future potential</article-title><source>Fungal Genet Biol.</source><year>2020</year><volume>137</volume><fpage>103333</fpage><pub-id pub-id-type="doi">10.1016/j.fgb.2020.103333</pub-id><pub-id pub-id-type="pmid">31923554</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Sen, S. &amp; Mansell, T. J. Yeasts as probiotics: mechanisms, outcomes, and future potential. <italic toggle="yes">Fungal Genet Biol.</italic><bold>137</bold>, 103333 (2020).<pub-id pub-id-type="pmid">31923554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fgb.2020.103333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Costea, P. I. et al. Enterotypes in the landscape of gut microbial community composition. <italic toggle="yes">Nat. Microbiol</italic>. <bold>3</bold>10.1038/s41564-017-0072-8 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-017-0072-8</pub-id><pub-id pub-id-type="pmcid">PMC5832044</pub-id><pub-id pub-id-type="pmid">29255284</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Enterotypes of the human gut mycobiome</article-title><source>Microbiome</source><year>2023</year><volume>11</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.1186/s40168-023-01586-y</pub-id><pub-id pub-id-type="pmid">37563687</pub-id><pub-id pub-id-type="pmcid">PMC10416509</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lai, S. et al. Enterotypes of the human gut mycobiome. <italic toggle="yes">Microbiome</italic><bold>11</bold>, 179 (2023).<pub-id pub-id-type="pmid">37563687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-023-01586-y</pub-id><pub-id pub-id-type="pmcid">PMC10416509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Vallet, N. et al. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. <italic toggle="yes">Cell Host Microbe</italic><bold>31</bold>10.1016/j.chom.2023.06.009 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2023.06.009</pub-id><pub-id pub-id-type="pmid">37463582</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Frioux, C. et al. Enterosignatures define common bacterial guilds in the human gut microbiome. <italic toggle="yes">Cell Host Microbe</italic><bold>31</bold>10.1016/j.chom.2023.05.024 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2023.05.024</pub-id><pub-id pub-id-type="pmid">37339626</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1126/science.abf3363</pub-id><pub-id pub-id-type="pmid">33542131</pub-id><pub-id pub-id-type="pmcid">PMC8097968</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <italic toggle="yes">Science</italic><bold>371</bold>, 595&#8211;602 (2021).<pub-id pub-id-type="pmid">33542131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf3363</pub-id><pub-id pub-id-type="pmcid">PMC8097968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Zhu, X. et al. A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy. <italic toggle="yes">Cell Host Microbe</italic><bold>32</bold>10.1016/j.chom.2024.03.002 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2024.03.002</pub-id><pub-id pub-id-type="pmid">38513657</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breuer</surname><given-names>U</given-names></name><name name-style="western"><surname>Harms</surname><given-names>H</given-names></name></person-group><article-title>Debaryomyces hansenii-an extremophilic yeast with biotechnological potential</article-title><source>Yeast</source><year>2006</year><volume>23</volume><fpage>415</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1002/yea.1374</pub-id><pub-id pub-id-type="pmid">16652409</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Breuer, U. &amp; Harms, H. Debaryomyces hansenii-an extremophilic yeast with biotechnological potential. <italic toggle="yes">Yeast</italic><bold>23</bold>, 415&#8211;437 (2006).<pub-id pub-id-type="pmid">16652409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/yea.1374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>AK</given-names></name><etal/></person-group><article-title>The gut mycobiome of the Human Microbiome Project healthy cohort</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0373-4</pub-id><pub-id pub-id-type="pmid">29178920</pub-id><pub-id pub-id-type="pmcid">PMC5702186</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Nash, A. K. et al. The gut mycobiome of the Human Microbiome Project healthy cohort. <italic toggle="yes">Microbiome</italic><bold>5</bold>, 153 (2017).<pub-id pub-id-type="pmid">29178920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-017-0373-4</pub-id><pub-id pub-id-type="pmcid">PMC5702186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>U</given-names></name><etal/></person-group><article-title>Debaryomyces is enriched in Crohn&#8217;s disease intestinal tissue and impairs healing in mice</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>1154</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1126/science.abd0919</pub-id><pub-id pub-id-type="pmid">33707263</pub-id><pub-id pub-id-type="pmcid">PMC10114606</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Jain, U. et al. Debaryomyces is enriched in Crohn&#8217;s disease intestinal tissue and impairs healing in mice. <italic toggle="yes">Science</italic><bold>371</bold>, 1154&#8211;1159 (2021).<pub-id pub-id-type="pmid">33707263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd0919</pub-id><pub-id pub-id-type="pmcid">PMC10114606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sz&#243;stak</surname><given-names>N</given-names></name><etal/></person-group><article-title>Host factors associated with gut mycobiome structure</article-title><source>mSystems</source><year>2023</year><volume>8</volume><fpage>e0098622</fpage><pub-id pub-id-type="doi">10.1128/msystems.00986-22</pub-id><pub-id pub-id-type="pmid">36786595</pub-id><pub-id pub-id-type="pmcid">PMC10134842</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Sz&#243;stak, N. et al. Host factors associated with gut mycobiome structure. <italic toggle="yes">mSystems</italic><bold>8</bold>, e0098622 (2023).<pub-id pub-id-type="pmid">36786595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/msystems.00986-22</pub-id><pub-id pub-id-type="pmcid">PMC10134842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1126/science.aan3706</pub-id><pub-id pub-id-type="pmid">29097494</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <italic toggle="yes">Science</italic><bold>359</bold>, 91&#8211;97 (2018).<pub-id pub-id-type="pmid">29097494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frankel</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients</article-title><source>Neoplasia</source><year>2017</year><volume>19</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.08.004</pub-id><pub-id pub-id-type="pmid">28923537</pub-id><pub-id pub-id-type="pmcid">PMC5602478</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. <italic toggle="yes">Neoplasia</italic><bold>19</bold>, 848&#8211;855 (2017).<pub-id pub-id-type="pmid">28923537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.08.004</pub-id><pub-id pub-id-type="pmcid">PMC5602478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matson</surname><given-names>V</given-names></name><etal/></person-group><article-title>The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1126/science.aao3290</pub-id><pub-id pub-id-type="pmid">29302014</pub-id><pub-id pub-id-type="pmcid">PMC6707353</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. <italic toggle="yes">Science</italic><bold>359</bold>, 104&#8211;108 (2018).<pub-id pub-id-type="pmid">29302014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aao3290</pub-id><pub-id pub-id-type="pmcid">PMC6707353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients</article-title><source>Genome Med.</source><year>2019</year><volume>11</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s13073-019-0672-4</pub-id><pub-id pub-id-type="pmid">31597568</pub-id><pub-id pub-id-type="pmcid">PMC6785875</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. <italic toggle="yes">Genome Med.</italic><bold>11</bold>, 61 (2019).<pub-id pub-id-type="pmid">31597568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-019-0672-4</pub-id><pub-id pub-id-type="pmcid">PMC6785875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>545</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01698-2</pub-id><pub-id pub-id-type="pmid">35228752</pub-id><pub-id pub-id-type="pmcid">PMC10246505</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 545&#8211;556 (2022).<pub-id pub-id-type="pmid">35228752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01698-2</pub-id><pub-id pub-id-type="pmcid">PMC10246505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>1632</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1126/science.aaz7015</pub-id><pub-id pub-id-type="pmid">34941392</pub-id><pub-id pub-id-type="pmcid">PMC8970537</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <italic toggle="yes">Science</italic><bold>374</bold>, 1632&#8211;1640 (2021).<pub-id pub-id-type="pmid">34941392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaz7015</pub-id><pub-id pub-id-type="pmcid">PMC8970537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id><pub-id pub-id-type="pmcid">PMC3322381</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Langmead, B. &amp; Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. <italic toggle="yes">Nat. Methods</italic><bold>9</bold>, 357&#8211;359 (2012).<pub-id pub-id-type="pmid">22388286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmcid">PMC3322381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>DE</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name></person-group><article-title>Improved metagenomic analysis with Kraken 2</article-title><source>Genome Biol.</source><year>2019</year><volume>20</volume><fpage>257</fpage><pub-id pub-id-type="doi">10.1186/s13059-019-1891-0</pub-id><pub-id pub-id-type="pmid">31779668</pub-id><pub-id pub-id-type="pmcid">PMC6883579</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Wood, D. E., Lu, J. &amp; Langmead, B. Improved metagenomic analysis with Kraken 2. <italic toggle="yes">Genome Biol.</italic><bold>20</bold>, 257 (2019).<pub-id pub-id-type="pmid">31779668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-019-1891-0</pub-id><pub-id pub-id-type="pmcid">PMC6883579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Ultrafast and accurate 16S rRNA microbial community analysis using Kraken 2</article-title><source>Microbiome</source><year>2020</year><volume>8</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.1186/s40168-020-00900-2</pub-id><pub-id pub-id-type="pmid">32859275</pub-id><pub-id pub-id-type="pmcid">PMC7455996</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Lu, J. &amp; Salzberg, S. L. Ultrafast and accurate 16S rRNA microbial community analysis using Kraken 2. <italic toggle="yes">Microbiome</italic><bold>8</bold>, 124 (2020).<pub-id pub-id-type="pmid">32859275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-020-00900-2</pub-id><pub-id pub-id-type="pmcid">PMC7455996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliev</surname><given-names>ID</given-names></name><name name-style="western"><surname>Cadwell</surname><given-names>K</given-names></name></person-group><article-title>Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases</article-title><source>Gastroenterology</source><year>2021</year><volume>160</volume><fpage>1050</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.06.100</pub-id><pub-id pub-id-type="pmid">33347881</pub-id><pub-id pub-id-type="pmcid">PMC7956156</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Iliev, I. D. &amp; Cadwell, K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. <italic toggle="yes">Gastroenterology</italic><bold>160</bold>, 1050&#8211;1066 (2021).<pub-id pub-id-type="pmid">33347881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.06.100</pub-id><pub-id pub-id-type="pmcid">PMC7956156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><etal/></person-group><article-title>Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin</article-title><source>Genome Biol.</source><year>2022</year><volume>23</volume><fpage>208</fpage><pub-id pub-id-type="doi">10.1186/s13059-022-02753-4</pub-id><pub-id pub-id-type="pmid">36192803</pub-id><pub-id pub-id-type="pmcid">PMC9531436</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Ma, S. et al. Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin. <italic toggle="yes">Genome Biol.</italic><bold>23</bold>, 208 (2022).<pub-id pub-id-type="pmid">36192803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-022-02753-4</pub-id><pub-id pub-id-type="pmcid">PMC9531436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>AT</given-names></name><name name-style="western"><surname>Katsyv</surname><given-names>I</given-names></name><name name-style="western"><surname>Song</surname><given-names>W-M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>DGCA: a comprehensive R package for differential gene correlation analysis</article-title><source>BMC Syst. Biol.</source><year>2016</year><volume>10</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s12918-016-0349-1</pub-id><pub-id pub-id-type="pmid">27846853</pub-id><pub-id pub-id-type="pmcid">PMC5111277</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">McKenzie, A. T., Katsyv, I., Song, W.-M., Wang, M. &amp; Zhang, B. DGCA: a comprehensive R package for differential gene correlation analysis. <italic toggle="yes">BMC Syst. Biol.</italic><bold>10</bold>, 106 (2016).<pub-id pub-id-type="pmid">27846853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12918-016-0349-1</pub-id><pub-id pub-id-type="pmcid">PMC5111277</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>